A Prospective Randomized Trial of VP-16 Plus G-CSF Plus Rituximab vs VP-16 Plus G-CSF Alone for Peripheral Blood Progenitor Cell ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2000-2006

ABSTRACT

RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. Giving etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with or without rituximab works in treating patients who are undergoing an autologous peripheral stem cell transplant for B-cell non-Hodgkin's lymphoma. Detailed Description OBJECTIVES: - Determine whether mobilization with etoposide and filgrastim (G-CSF) with or without rituximab influences CD34+ cell yield in patients undergoing autologous peripheral blood stem cell transplantation for B-cell non-Hodgkin's lymphoma. - Determine the acute toxicity of rituximab in combination with etoposide and G-CSF for peripheral blood stem cell mobilization in these patients. OUTLINE: This is a randomized study. - Stem cell mobilization: Patients are randomized to 1 of 2 mobilization arms. - Arm I: Patients receive rituximab IV over 4 hours on days 1, 8, and 15. Patients also receive etoposide IV over 4 hours on day 15 and filgrastim (G-CSF) subcutaneously (SC) beginning on day 17 and continuing until approximately day 25. Patients then undergo apheresis over 5 days or until an adequate amount of stem cells are collected. After stem cell collection is completed, patients proceed to the preparative regimen. - Arm II: Patients receive etoposide IV over 4 hours on day 1 and G-CSF SC beginning on day 3 and continuing until approximately day 11. Patients then undergo apheresis over 5 days or until an adequate amount of stem cells are collected. After stem cell collection is completed, patients proceed to the preparative regimen. - Preparative regimen: Patients receive oral busulfan once daily on days -8 to -4, etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 2 hours on days -3 and -2. - Autologous peripheral blood stem cell transplantation (PBSCT): Patients undergo autologous PBSCT on day 0. Beginning on day 5, patients receive G-CSF SC or IV once daily until blood counts recover. After completion study treatment, patients are followed periodically for 10 years. PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study. More... »

URL

https://clinicaltrials.gov/show/NCT00274794

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. Giving etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with or without rituximab works in treating patients who are undergoing an autologous peripheral stem cell transplant for B-cell non-Hodgkin's lymphoma.\n\nDetailed Description\nOBJECTIVES: - Determine whether mobilization with etoposide and filgrastim (G-CSF) with or without rituximab influences CD34+ cell yield in patients undergoing autologous peripheral blood stem cell transplantation for B-cell non-Hodgkin's lymphoma. - Determine the acute toxicity of rituximab in combination with etoposide and G-CSF for peripheral blood stem cell mobilization in these patients. OUTLINE: This is a randomized study. - Stem cell mobilization: Patients are randomized to 1 of 2 mobilization arms. - Arm I: Patients receive rituximab IV over 4 hours on days 1, 8, and 15. Patients also receive etoposide IV over 4 hours on day 15 and filgrastim (G-CSF) subcutaneously (SC) beginning on day 17 and continuing until approximately day 25. Patients then undergo apheresis over 5 days or until an adequate amount of stem cells are collected. After stem cell collection is completed, patients proceed to the preparative regimen. - Arm II: Patients receive etoposide IV over 4 hours on day 1 and G-CSF SC beginning on day 3 and continuing until approximately day 11. Patients then undergo apheresis over 5 days or until an adequate amount of stem cells are collected. After stem cell collection is completed, patients proceed to the preparative regimen. - Preparative regimen: Patients receive oral busulfan once daily on days -8 to -4, etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 2 hours on days -3 and -2. - Autologous peripheral blood stem cell transplantation (PBSCT): Patients undergo autologous PBSCT on day 0. Beginning on day 5, patients receive G-CSF SC or IV once daily until blood counts recover. After completion study treatment, patients are followed periodically for 10 years. PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.", 
    "endDate": "2006-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00274794", 
    "keywords": [
      "prospective randomized trial", 
      "Plus", 
      "peripheral blood progenitor cell", 
      "autologous stem cell transplantation", 
      "lymphoid malignancy", 
      "rationale", 
      "drug", 
      "Drug Therapy", 
      "busulfan", 
      "etoposide", 
      "cyclophosphamide", 
      "different way", 
      "stop", 
      "cancer cell", 
      "Homicide", 
      "cell", 
      "Colony-Stimulating Factor", 
      "Granulocyte Colony-Stimulating Factor", 
      "monoclonal antibody", 
      "rituximab", 
      "stem cell", 
      "bone marrow", 
      "blood", 
      "Transplant", 
      "stem cell transplant", 
      "effective treatment", 
      "lymphoma", 
      "randomized clinical trial", 
      "patient", 
      "B-Lymphocytes", 
      "Determine", 
      "mobilization", 
      "CD34+ cell", 
      "peripheral blood stem cell", 
      "acute toxicity", 
      "outline", 
      "randomized study", 
      "Hematopoietic Stem Cell Mobilization", 
      "arm", 
      "SC", 
      "Blood Component Removal", 
      "adequate amount", 
      "preparative regimen", 
      "beginning", 
      "CSF", 
      "blood count", 
      "study treatment", 
      "accrual"
    ], 
    "name": "A Prospective Randomized Trial of VP-16 Plus G-CSF Plus Rituximab vs VP-16 Plus G-CSF Alone for Peripheral Blood Progenitor Cell Mobilization Prior to Autologous Stem Cell Transplantation for B Cell Lymphoid Malignancies", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00274794"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00002.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.239578.2", 
        "type": "Organization"
      }
    ], 
    "startDate": "2000-02-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/bmt.2008.306", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027730906", 
          "https://doi.org/10.1038/bmt.2008.306"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00274794"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00274794'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00274794'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00274794'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00274794'


 

This table displays all metadata directly associated to this object as RDF triples.

76 TRIPLES      16 PREDICATES      66 URIs      57 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00274794 schema:about anzsrc-for:3048
2 anzsrc-for:3142
3 schema:description RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. Giving etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with or without rituximab works in treating patients who are undergoing an autologous peripheral stem cell transplant for B-cell non-Hodgkin's lymphoma. Detailed Description OBJECTIVES: - Determine whether mobilization with etoposide and filgrastim (G-CSF) with or without rituximab influences CD34+ cell yield in patients undergoing autologous peripheral blood stem cell transplantation for B-cell non-Hodgkin's lymphoma. - Determine the acute toxicity of rituximab in combination with etoposide and G-CSF for peripheral blood stem cell mobilization in these patients. OUTLINE: This is a randomized study. - Stem cell mobilization: Patients are randomized to 1 of 2 mobilization arms. - Arm I: Patients receive rituximab IV over 4 hours on days 1, 8, and 15. Patients also receive etoposide IV over 4 hours on day 15 and filgrastim (G-CSF) subcutaneously (SC) beginning on day 17 and continuing until approximately day 25. Patients then undergo apheresis over 5 days or until an adequate amount of stem cells are collected. After stem cell collection is completed, patients proceed to the preparative regimen. - Arm II: Patients receive etoposide IV over 4 hours on day 1 and G-CSF SC beginning on day 3 and continuing until approximately day 11. Patients then undergo apheresis over 5 days or until an adequate amount of stem cells are collected. After stem cell collection is completed, patients proceed to the preparative regimen. - Preparative regimen: Patients receive oral busulfan once daily on days -8 to -4, etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 2 hours on days -3 and -2. - Autologous peripheral blood stem cell transplantation (PBSCT): Patients undergo autologous PBSCT on day 0. Beginning on day 5, patients receive G-CSF SC or IV once daily until blood counts recover. After completion study treatment, patients are followed periodically for 10 years. PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.
4 schema:endDate 2006-05-01T00:00:00Z
5 schema:keywords B-Lymphocytes
6 Blood Component Removal
7 CD34+ cell
8 CSF
9 Colony-Stimulating Factor
10 Determine
11 Drug Therapy
12 Granulocyte Colony-Stimulating Factor
13 Hematopoietic Stem Cell Mobilization
14 Homicide
15 Plus
16 SC
17 Transplant
18 accrual
19 acute toxicity
20 adequate amount
21 arm
22 autologous stem cell transplantation
23 beginning
24 blood
25 blood count
26 bone marrow
27 busulfan
28 cancer cell
29 cell
30 cyclophosphamide
31 different way
32 drug
33 effective treatment
34 etoposide
35 lymphoid malignancy
36 lymphoma
37 mobilization
38 monoclonal antibody
39 outline
40 patient
41 peripheral blood progenitor cell
42 peripheral blood stem cell
43 preparative regimen
44 prospective randomized trial
45 randomized clinical trial
46 randomized study
47 rationale
48 rituximab
49 stem cell
50 stem cell transplant
51 stop
52 study treatment
53 schema:name A Prospective Randomized Trial of VP-16 Plus G-CSF Plus Rituximab vs VP-16 Plus G-CSF Alone for Peripheral Blood Progenitor Cell Mobilization Prior to Autologous Stem Cell Transplantation for B Cell Lymphoid Malignancies
54 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00274794
55 schema:sdDatePublished 2019-03-07T15:21
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher Nfee23907b53f48baafd758423a381507
58 schema:sponsor https://www.grid.ac/institutes/grid.239578.2
59 https://www.grid.ac/institutes/grid.48336.3a
60 schema:startDate 2000-02-01T00:00:00Z
61 schema:subjectOf sg:pub.10.1038/bmt.2008.306
62 schema:url https://clinicaltrials.gov/show/NCT00274794
63 sgo:license sg:explorer/license/
64 sgo:sdDataset clinical_trials
65 rdf:type schema:MedicalStudy
66 Nfee23907b53f48baafd758423a381507 schema:name Springer Nature - SN SciGraph project
67 rdf:type schema:Organization
68 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
69 rdf:type schema:DefinedTerm
70 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
71 rdf:type schema:DefinedTerm
72 sg:pub.10.1038/bmt.2008.306 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027730906
73 https://doi.org/10.1038/bmt.2008.306
74 rdf:type schema:CreativeWork
75 https://www.grid.ac/institutes/grid.239578.2 schema:Organization
76 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...